Movement Alert|Axsome Therapeutics Intraday Rise 5.42%, Q3 earnings beat and maintained outperform view support rebound

Market Focus11-03

On November 3, Axsome Therapeutics rose 5.42% in Regular Trading, trading at $144.34/share, with turnover of $20.9998 million.

The move followed stronger-than-expected third-quarter results and a subsequent maintained outperform rating from a major bank, even as its price target was trimmed to $273 from $295.

Axsome Therapeutics reported a third-quarter adjusted loss of $0.25 per share, better than consensus expectations of about $0.56 to $0.68, while revenue reached $259.7 million, above forecasts near $249 million to $250 million and up about 52% year over year. Net loss narrowed to about $12.9 million from $47.2 million a year earlier, reflecting continued commercial momentum led by Auvelity. Additional recent company developments include a settlement resolving SUNOSI patent litigation and an AXS-12 narcolepsy decision date set for May 1, 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment